A comprehensive view of Sanofi SA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
Sanofi SA Champions Early Diagnosis and Quality of Life in Rare Diseases and Chronic Conditions, Impacting Over 30 Million in Europe
Published: April 20, 2024 by Industry Intelligence Inc.
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA
Sanofi announces undisclosed number of layoffs as part of a new vision to become an immunoscience powerhouse; head of R&D revealed the company's plans following an extensive review, leading to a 'pipeline reprioritization project'
Published: April 05, 2024 by FierceBiotech
Sanofi SA Boosts Public Health with Adolescent Immunization Advocacy and Pioneers in Rare Disease Management while Capitalizing on E-Commerce Trends
Published: April 03, 2024 by Industry Intelligence Inc.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count